Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women’s health.
The Company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer.
Find out about company announcements, latest shareholder newsletters and our recent activities in the news. more
For investor relations, please contact firstname.lastname@example.org
A Clearer Picture of Breast Cancer Risk
1 in 11 women will develop breast cancer in their lifetime. With a market potential of $600 million per annum, BREVAGenPlus is a cost effective test that helps women assess their sporadic
breast cancer risk.